Literature DB >> 18026741

Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences.

Shinsuke Kato1.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily involves the motor neuron system. The author initially summarizes the principal features of human ALS neuropathology, and subsequently describes in detail ALS animal models mainly from the viewpoint of pathological similarities and differences. ALS animal models in this review include strains of rodents that are transgenic for superoxide dismutase 1 (SOD1), ALS2 knockout mice, and mice that are transgenic for cytoskeletal abnormalities. Although the neuropathological results obtained from human ALS autopsy cases are valuable and important, almost all of such cases represent only the terminal stage. This makes it difficult to clarify how and why ALS motor neurons are impaired at each clinical stage from disease onset to death, and as a consequence, human autopsy cases alone yield little insight into potential therapies for ALS. Although ALS animal models cannot replicate human ALS, in order to compensate for the shortcomings of studies using human ALS autopsy samples, researchers must inevitably rely on ALS animal models that can yield very important information for clarifying the pathogenesis of ALS in humans and for the establishment of reliable therapy. Of course, human ALS and all ALS animal models share one most important similarity in that both exhibit motor neuron degeneration/death. This important point of similarity has shed much light on the pathomechanisms of the motor neuron degeneration/death at the cellular and molecular levels that would not have been appreciated if only human ALS autopsy samples had been available. On the basis of the aspects covered in this review, it can be concluded that ALS animal models can yield very important information for clarifying the pathogenesis of ALS in humans and for the establishment of reliable therapy only in combination with detailed neuropathological data obtained from human ALS autopsy cases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026741     DOI: 10.1007/s00401-007-0308-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  41 in total

1.  Naturally occurring genetic variability in expression of Gsta4 is associated with differential survival of axotomized rat motoneurons.

Authors:  Mikael Ström; Faiez Al Nimer; Rickard Lindblom; Jens Randel Nyengaard; Fredrik Piehl
Journal:  Neuromolecular Med       Date:  2011-12-08       Impact factor: 3.843

Review 2.  Inhibitory synaptic regulation of motoneurons: a new target of disease mechanisms in amyotrophic lateral sclerosis.

Authors:  Lee J Martin; Qing Chang
Journal:  Mol Neurobiol       Date:  2011-11-10       Impact factor: 5.590

3.  Longitudinal monitoring of motor neuron circuitry in FALS rats using in-vivo phMRI.

Authors:  Ji-Kyung Choi; Alpaslan Dedeoglu; Bruce G Jenkins
Journal:  Neuroreport       Date:  2010-02-17       Impact factor: 1.837

4.  Nonamyloid aggregates arising from mature copper/zinc superoxide dismutases resemble those observed in amyotrophic lateral sclerosis.

Authors:  Young-Mi Hwang; Peter B Stathopulos; Kristin Dimmick; Hong Yang; Hamid R Badiei; Ming Sze Tong; Jessica A O Rumfeldt; Pu Chen; Vassili Karanassios; Elizabeth M Meiering
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

5.  Quantity and activation of myofiber-associated satellite cells in a mouse model of amyotrophic lateral sclerosis.

Authors:  Raquel Manzano; Janne M Toivonen; Ana Cristina Calvo; Sara Oliván; Pilar Zaragoza; Maria Jesús Muñoz; Didier Montarras; Rosario Osta
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

6.  A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration.

Authors:  Masataka Nakamura; Kevin F Bieniek; Wen-Lang Lin; Neill R Graff-Radford; Melissa E Murray; Monica Castanedes-Casey; Pamela Desaro; Matthew C Baker; Nicola J Rutherford; Janice Robertson; Rosa Rademakers; Dennis W Dickson; Kevin B Boylan
Journal:  Acta Neuropathol       Date:  2015-04-28       Impact factor: 17.088

Review 7.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

8.  Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis.

Authors:  Tomoyuki Awano; Gary S Johnson; Claire M Wade; Martin L Katz; Gayle C Johnson; Jeremy F Taylor; Michele Perloski; Tara Biagi; Izabella Baranowska; Sam Long; Philip A March; Natasha J Olby; G Diane Shelton; Shahnawaz Khan; Dennis P O'Brien; Kerstin Lindblad-Toh; Joan R Coates
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

9.  Loss of ALS2/Alsin exacerbates motor dysfunction in a SOD1-expressing mouse ALS model by disturbing endolysosomal trafficking.

Authors:  Shinji Hadano; Asako Otomo; Ryota Kunita; Kyoko Suzuki-Utsunomiya; Akira Akatsuka; Masato Koike; Masashi Aoki; Yasuo Uchiyama; Yasuto Itoyama; Joh-E Ikeda
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

10.  Mutant SOD1 impairs axonal transport of choline acetyltransferase and acetylcholine release by sequestering KAP3.

Authors:  Minako Tateno; Shinsuke Kato; Takashi Sakurai; Nobuyuki Nukina; Ryosuke Takahashi; Toshiyuki Araki
Journal:  Hum Mol Genet       Date:  2008-12-16       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.